crowdfundingCan HIV be “controlled” by a vaccine? That’s the hope of one nonprofit organization, who successfully raised crowdfunding cash. Image credit: Wikimedia Commons.

We have recently discussed here how crowdfunding — donations from the general public in support of a cause, idea, or invention — has caught the attention of scientists seeking financial backing in an era of tight budgets. The brave new world of crowdfunding in science raises questions that defy easy answers. What is essential to lead a successful crowdfunding campaign? Is it possible to win the hearts and minds of laypeople AND impress one’s scientific peers?

A case in point is the recent crowdfunding campaign by the nonprofit corporation Immunity Project. The organization has noted that about 1 out of 300 people are HIV “controllers”, meaning that, although they might wind up with a low level of HIV, the virus may be kept in check. The Immunity Project hopes to come out with a vaccine that would endow everyone with the same immunity enjoyed by the controllers. The organization hopes to have a vaccine ready in 2016, and it would be provided at no charge. The money it sought was for a final experiment before Phase I clinical testing.

Some of the reaction from the scientific community, however, has been more than a little critical:

“The concept they’re selling is an old concept that has been shown not to work, and it can’t work.”[1]

“It seems like they’re going straight to the public and making appeals to emotion because they don’t have the scientific background to establish themselves in the research community.”[1]

One point that has raised a number of eyebrows is the lack of publications that support the organization’s approach. CEO Reid Rubsamen has reported that an article has been submitted to a peer-reviewed journal. Rubsamen was the host of an “Ask Me Anything” segment on the social networking service Reddit. Hundreds of comments and questions poured in. Some people expressed doubts and concerns. But many others articulated their enthusiasm, even if they were not experts themselves:

“I donated. I have no idea if what you’re doing is feasible or not, but it looks to me like you’re taking a brand new (or at least uncommon) approach to medical research, and that excites me.”[2]

A few held contempt for established institutions and commended Immunity Project’s undertaking as a humanitarian alternative:

“It restores some of my faith in humanity knowing that there are people like you out there. Pharmaceutical companies are among the most evil corporations out there. Where they are looking for a vaccine only to provide to the wealthiest of nations and make billions in profits, your team is trying to actually provide a service to humanity.”[2]

In Reddit and elsewhere, there have been enough fans that Immunity Project was able to meet its crowdfunding goal of $462,000. (Four people individually donated $50,000.) This amount is not particularly a king’s ransom in science dollars, and the group has needed to make every dollar count, including finding a discounted flow cytometer. (Flow cytometry, with many vendors offering their services through Assay Depot, is widely applied to vaccine research.)

Regardless of whether Immunity Project succeeds or not, it is the nature of research that many, if not most, scientific projects supported by crowdfunding will not pan out. Will that mean that supporters will grow disillusioned and snap their wallets shut? Or is the excitement of backing a venture at the edge of knowledge enough for donors to come back again and again? This is one experiment whose results are not yet in.

References

1. Hayden, E.C. (2014) Crowd-funded HIV vaccine project sparks debate. Nature. doi:10.1038/nature.2014.14675

2. http://www.reddit.com/r/IAmA/comments/1w29dx/we_are_creating_the_hivaids_vaccine_to_give_away/

Posted 12:28 pm,

Connecting academic scientists to the global life science ecosystem Like everyone else, academic researchers are finding that funding sources are drying up and that they somehow must do more research work with less money. To do something about it, a group of Universities in Missouri and Kansas have teamed up with Assay Depot to create […]

Read More...
Posted 11:39 am,

As we previously discussed, CRISPR-mania is sweeping the globe. (Okay, it might not be as big as Beatlemania, but more than a few life science researchers have probably squealed in delight.) The CRISPR system, derived from bacteria’s fight against viruses and tailored so that it can snip away genetic material in other organisms, has generated […]

Read More...
Posted 2:26 pm,

It’s a sad story that everyone is familiar with: A patient takes one or more well-known cancer drugs, and they work — for a while. However, after the respite, the cancer comes roaring back, this time impervious to the once powerful effects of the cancer drugs. Many people would view the disease’s return with resignation […]

Read More...
Posted 1:52 pm,

Over the course of this series so far we’ve looked at the role of the microbiome in two of the three major therapeutic areas targeted by drug discoverers.  Now comes the third and final segment and it’s a big one:  Cancer.  For many people the role of the microbiome in inflammation and metabolism is unsurprising.  Your […]

Read More...
Posted 4:08 pm,

The vast majority of compounds that enter clinical trials fail to make it through. The result: few drugs, plenty of bills. The consensus in drug discovery is that things need to change. Part of the problem is the maze that is human biology. Choosing the “right” drug target is difficult when 1) information is incomplete, […]

Read More...
Posted 11:07 am,

Outsourcing has proven to reduce costs while dramatically improving productivity of the drug discovery process. Primary benefits to outsourcing drug discovery include higher quality services, direct cost savings, reduced time to clinic, and enhanced innovation. [1] Case in point: Anika Therapeutics recently won FDA Pre-Market Approval for the new osteoarthritis treatment, Monovisc. One of the […]

Read More...
Posted 10:55 am,

Having introduced the “Age of the Microbiome in Drug Discovery” and the “The Microbiome in Metabolic Disease” we now turn to the influence of the microbiome in inflammation.  Dr. Andrew Johnson of the University of California again gave us his thoughts on this emergent therapeutic area. There is little need for an introduction into the […]

Read More...
Posted 1:47 pm,

A fluorescent tag, also known as a label or probe, is a molecule that is chemically attached to a biomolecule such as a protein, antibody, or synthetic compound, in order to aid in labeling and detection. Scientists have been using tags for well over a century as research tools, but here we discuss some of […]

Read More...
Posted 8:00 pm,

With the rise of next-generation sequencing and the increase of big data, scientists have gained a deeper understanding of various diseases. So it may seem counter-intuitive that even with greater understanding and data there has not been a proportional increase in new drugs on the market by big pharma. Most new drugs do not reach […]

Read More...
Posted 8:00 am,